Front Row Advisors LLC Genmab A/S Transaction History

Front Row Advisors LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$25.13 - $30.27 $175 - $211	7 Added 4.76%	154 $3,000
Q1 2024 May 14, 2024	BUY	$26.43 - $32.77 $3,885 - $4,817	147 New	147 $4,000
Q3 2023 Nov 15, 2023	BUY	$35.27 - $42.24 $141 - $168	4 Added 2.84%	145 $5,000
Q2 2023 Aug 14, 2023	SELL	$37.4 - $42.94 $149 - $171	-4 Reduced 2.76%	141 $5,000
Q1 2023 May 22, 2023	BUY	$34.88 - $43.22 $4,883 - $6,050	140 Added 2800.0%	145 $5,000
Q1 2023 May 15, 2023	SELL	$34.88 - $43.22 $4,813 - $5,964	-138 Reduced 96.5%	5 $15,000
Q4 2022 Feb 15, 2023	SELL	$33.8 - $47.06 $3,109 - $4,329	-92 Reduced 39.15%	143 $6,000
Q3 2022 Nov 15, 2022	BUY	$31.52 - $373.61 $315 - $3,736	10 Added 4.44%	235 $8,000
Q2 2022 Aug 15, 2022	BUY	$26.83 - $38.57 $80 - $115	3 Added 1.35%	225 $7,000
Q1 2022 May 11, 2022	BUY	$30.95 - $39.68 $154 - $198	5 Added 2.3%	222 $8,000
Q4 2021 Mar 09, 2022	SELL	$35.87 - $47.12 $179 - $235	-5 Reduced 2.25%	217 $9,000
Q2 2021 Aug 23, 2021	BUY	$32.88 - $44.57 $230 - $311	7 Added 3.26%	222 $10,000
Q1 2021 Apr 28, 2021	SELL	$30.92 - $44.4 $61 - $88	-2 Reduced 0.92%	215 $7,000
Q4 2020 Feb 25, 2021	SELL	$33.66 - $40.76 $67 - $81	-2 Reduced 0.91%	217 $9,000
Q3 2020 Nov 30, 2020	BUY	$33.07 - $38.68 $7,242 - $8,470	219 New	219 $8,000

234

52.5M

10.2K

25.5K

Ticker GMAB
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 658,292,992
Market Cap $13.8B
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...

Get notified when there are updates to the investment portfolio of Front Row Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Front Row Advisors LLC with notifications on news.